Wedbush downgraded shares of Alto Neuroscience (NYSE:ANRO – Free Report) from an outperform rating to a neutral rating in a report issued on Wednesday, Marketbeat.com reports. The firm currently has $4.00 price target on the stock, down from their prior price target of $29.00.
Several other analysts also recently weighed in on the company. William Blair reiterated an “outperform” rating on shares of Alto Neuroscience in a research report on Tuesday, September 10th. Rodman & Renshaw lowered shares of Alto Neuroscience from a “buy” rating to a “neutral” rating in a report on Wednesday. Finally, Robert W. Baird dropped their target price on shares of Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating on the stock in a research note on Wednesday. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $24.40.
Check Out Our Latest Stock Report on ANRO
Alto Neuroscience Stock Performance
Alto Neuroscience (NYSE:ANRO – Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.60) earnings per share for the quarter, topping the consensus estimate of ($0.67) by $0.07. As a group, research analysts anticipate that Alto Neuroscience will post -2.63 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in the business. RA Capital Management L.P. purchased a new stake in shares of Alto Neuroscience in the 1st quarter worth approximately $21,267,000. Price T Rowe Associates Inc. MD bought a new position in Alto Neuroscience in the first quarter worth approximately $9,788,000. Vanguard Group Inc. purchased a new stake in Alto Neuroscience during the first quarter worth $8,233,000. Jennison Associates LLC bought a new stake in Alto Neuroscience during the 1st quarter valued at $7,039,000. Finally, Artal Group S.A. purchased a new position in shares of Alto Neuroscience in the 1st quarter valued at $5,372,000.
About Alto Neuroscience
Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.
Read More
- Five stocks we like better than Alto Neuroscience
- How to Calculate Inflation Rate
- Texas Roadhouse Stock Steering for New Highs This Year
- How to Choose Top Rated Stocks
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Most Volatile Stocks, What Investors Need to Know
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Alto Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alto Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.